ES2769255T3 - Métodos para fabricar inhibidores de la proteína desacetilasa - Google Patents
Métodos para fabricar inhibidores de la proteína desacetilasa Download PDFInfo
- Publication number
- ES2769255T3 ES2769255T3 ES16732810T ES16732810T ES2769255T3 ES 2769255 T3 ES2769255 T3 ES 2769255T3 ES 16732810 T ES16732810 T ES 16732810T ES 16732810 T ES16732810 T ES 16732810T ES 2769255 T3 ES2769255 T3 ES 2769255T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- converting
- acid
- particular embodiment
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *=C(c1cnc(N(c2ccccc2)c(cccc2)c2Cl)nc1)NCCCCCCC(NO)=O Chemical compound *=C(c1cnc(N(c2ccccc2)c(cccc2)c2Cl)nc1)NCCCCCCC(NO)=O 0.000 description 7
- IEMKQRSOAOPKRJ-UHFFFAOYSA-N CCOC(c(cn1)cnc1Cl)=O Chemical compound CCOC(c(cn1)cnc1Cl)=O IEMKQRSOAOPKRJ-UHFFFAOYSA-N 0.000 description 1
- UNZANUODCGDKAV-UHFFFAOYSA-N CCOC(c1cnc(N(c2ccccc2)c(cccc2)c2Cl)nc1)=O Chemical compound CCOC(c1cnc(N(c2ccccc2)c(cccc2)c2Cl)nc1)=O UNZANUODCGDKAV-UHFFFAOYSA-N 0.000 description 1
- PBBZQYXRCHGAKJ-UHFFFAOYSA-N CCOC(c1cnc(N(c2ccccc2)c2cccc(Cl)c2)nc1)=O Chemical compound CCOC(c1cnc(N(c2ccccc2)c2cccc(Cl)c2)nc1)=O PBBZQYXRCHGAKJ-UHFFFAOYSA-N 0.000 description 1
- ZUKQDXJKYIIHBW-UHFFFAOYSA-N CCOC(c1cnc(N(c2ccccc2)c2ccccc2)nc1)=O Chemical compound CCOC(c1cnc(N(c2ccccc2)c2ccccc2)nc1)=O ZUKQDXJKYIIHBW-UHFFFAOYSA-N 0.000 description 1
- ZGDNUSLFBDDDJT-UHFFFAOYSA-N CCOC(c1cnc(Nc2ccccc2Cl)nc1)=O Chemical compound CCOC(c1cnc(Nc2ccccc2Cl)nc1)=O ZGDNUSLFBDDDJT-UHFFFAOYSA-N 0.000 description 1
- VGJWPMYIXKPLJU-UHFFFAOYSA-N COC(CCCCCCNC(c1cnc(N(c2ccccc2)c(cccc2)c2Cl)nc1)=O)=O Chemical compound COC(CCCCCCNC(c1cnc(N(c2ccccc2)c(cccc2)c2Cl)nc1)=O)=O VGJWPMYIXKPLJU-UHFFFAOYSA-N 0.000 description 1
- KVCUEYZPPXIXMV-UHFFFAOYSA-N OC(c1cnc(N(c2ccccc2)c(cccc2)c2Cl)nc1)=O Chemical compound OC(c1cnc(N(c2ccccc2)c(cccc2)c2Cl)nc1)=O KVCUEYZPPXIXMV-UHFFFAOYSA-N 0.000 description 1
- VLIUIBXPEDFJRF-UHFFFAOYSA-N ONC(CCCCCCNC(c1cnc(N(c2ccccc2)c(cccc2)c2Cl)nc1)=O)=O Chemical compound ONC(CCCCCCNC(c1cnc(N(c2ccccc2)c(cccc2)c2Cl)nc1)=O)=O VLIUIBXPEDFJRF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/30—Halogen atoms or nitro radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562172624P | 2015-06-08 | 2015-06-08 | |
| PCT/US2016/036434 WO2016200930A1 (en) | 2015-06-08 | 2016-06-08 | Methods of making protein deacetylase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2769255T3 true ES2769255T3 (es) | 2020-06-25 |
Family
ID=56264043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16732810T Active ES2769255T3 (es) | 2015-06-08 | 2016-06-08 | Métodos para fabricar inhibidores de la proteína desacetilasa |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10144714B2 (enExample) |
| EP (1) | EP3303304B1 (enExample) |
| JP (1) | JP6873053B2 (enExample) |
| CN (1) | CN107922352B (enExample) |
| AR (1) | AR105812A1 (enExample) |
| AU (2) | AU2016276573A1 (enExample) |
| CA (1) | CA2988594C (enExample) |
| ES (1) | ES2769255T3 (enExample) |
| MX (1) | MX369349B (enExample) |
| TW (1) | TWI706937B (enExample) |
| WO (1) | WO2016200930A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2526093T3 (pl) * | 2010-01-22 | 2017-02-28 | Acetylon Pharmaceuticals, Inc. | Odwrócone związki amidowe jako inhibitory deacetylazy białkowej oraz sposoby ich stosowania |
| HK1207403A1 (en) | 2012-04-19 | 2016-01-29 | Acetylon Pharmaceuticals, Inc. | Biomarkers to identify patients that will respond to treatment and treating such patients |
| AR104935A1 (es) | 2015-06-08 | 2017-08-23 | Acetylon Pharmaceuticals Inc | Formas cristalinas de un inhibidor de histona deacetilasa |
| TWI706937B (zh) | 2015-06-08 | 2020-10-11 | 美商艾斯特隆製藥公司 | 製備蛋白質去乙醯酶抑制劑之方法 |
| EP3468559B1 (en) * | 2016-06-09 | 2023-11-22 | Dana Farber Cancer Institute, Inc. | Methods of use and pharmaceutical combinations of hdac inhibitors with bet inhibitors |
| JP7100018B2 (ja) | 2016-08-08 | 2022-07-12 | アセチロン ファーマシューティカルズ インコーポレイテッド | ヒストンデアセチラーゼ６阻害剤及びｃｄ２０阻害抗体の薬学的組み合わせならびにその使用 |
| EP3544600A4 (en) | 2016-11-23 | 2020-06-17 | Acetylon Pharmaceuticals, Inc. | PHARMACEUTICAL COMBINATIONS WITH A HISTONE DEACETYLAS INHIBITOR AND A PROGRAMMED DEATH LIGAND-1 (PD-L1) INHIBITOR AND METHOD FOR USE THEREOF |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
| US20030129724A1 (en) | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
| JP2003528074A (ja) | 2000-03-24 | 2003-09-24 | メチルジーン インコーポレイテッド | ヒストン脱アセチル化酵素の阻害剤 |
| WO2002074298A1 (en) | 2001-03-21 | 2002-09-26 | Ono Pharmaceutical Co., Ltd. | Il-6 production inhibitors |
| US7244853B2 (en) | 2001-05-09 | 2007-07-17 | President And Fellows Of Harvard College | Dioxanes and uses thereof |
| AU2002363174B2 (en) | 2001-11-01 | 2008-09-25 | Janssen Pharmaceutica N.V. | Amide derivatives as glycogen synthase kinase 3-beta inhibitors |
| US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US7375228B2 (en) | 2003-03-17 | 2008-05-20 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| EP1644323B1 (en) | 2003-07-07 | 2015-03-18 | Georgetown University | Histone deacetylase inhibitors and methods of use thereof |
| CA2561617A1 (en) | 2004-04-05 | 2005-10-20 | Aton Pharma, Inc. | Histone deacetylase inhibitor prodrugs |
| SG171690A1 (en) | 2005-03-22 | 2011-06-29 | Harvard College | Treatment of protein degradation disorders |
| CA2620414A1 (en) | 2005-08-26 | 2007-03-01 | Methylgene Inc. | Benzodiazepine and benzopiperazine analog inhibitors of histone deacetylase |
| WO2008091349A1 (en) | 2006-02-14 | 2008-07-31 | The President And Fellows Of Harvard College | Bifunctional histone deacetylase inhibitors |
| WO2007130429A2 (en) | 2006-05-03 | 2007-11-15 | The President And Fellows Of Harvard College | Histone deacetylase and tubulin deacetylase inhibitors |
| WO2007144341A1 (en) | 2006-06-12 | 2007-12-21 | Vrije Universiteit Brussel | Differentiation of rat liver epithelial cells into hepatocyte-like cells |
| ES2288802B1 (es) | 2006-07-07 | 2008-12-16 | Universidad De Granada | Nuevos derivados de ftalimida como inhibidores de las histonas desacetilasas. |
| WO2008033746A2 (en) | 2006-09-11 | 2008-03-20 | Curis, Inc. | Tyrosine kinase inhibitors containing a zinc binding moiety |
| TWI478709B (zh) | 2008-02-19 | 2015-04-01 | Earnest Medicine Co Ltd | A useful oral or enteral composition for the recovery of bodily functions |
| EP2321264B1 (en) | 2008-07-23 | 2016-05-04 | President and Fellows of Harvard College | Deacetylase inhibitors and uses thereof |
| US8716326B2 (en) | 2009-05-15 | 2014-05-06 | Korea Research Institute Of Chemical Technology | Isoindolinone derivatives, preparation method thereof and a pharmaceutical composition comprising same |
| US8716344B2 (en) | 2009-08-11 | 2014-05-06 | President And Fellows Of Harvard College | Class- and isoform-specific HDAC inhibitors and uses thereof |
| AU2010331927B2 (en) * | 2009-12-17 | 2013-10-10 | Merck Canada Inc. | Aminopyrimidines as Syk inhibitors |
| WO2011084991A2 (en) | 2010-01-08 | 2011-07-14 | President And Fellows Of Harvard College | Fluorinated hdac inhibitors and uses thereof |
| PL2526093T3 (pl) | 2010-01-22 | 2017-02-28 | Acetylon Pharmaceuticals, Inc. | Odwrócone związki amidowe jako inhibitory deacetylazy białkowej oraz sposoby ich stosowania |
| EP2571352A4 (en) | 2010-05-21 | 2014-09-17 | Sloan Kettering Inst Cancer | SELECTIVE HDAC HEMMER |
| WO2012018499A2 (en) | 2010-08-05 | 2012-02-09 | Acetylon Pharmaceuticals | Specific regulation of cytokine levels by hdac6 inhibitors |
| NZ610225A (en) | 2010-11-16 | 2015-08-28 | Acetylon Pharmaceuticals Inc | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof |
| EP2734500A4 (en) | 2011-07-20 | 2015-04-08 | Gen Hospital Corp | SELECTIVE HISTONDEACETYLASE-6 INHIBITORS FOR THE TREATMENT OF BONE DISORDERS |
| EP2760843B1 (en) | 2011-09-26 | 2016-03-02 | Bristol-Myers Squibb Company | Selective nr2b antagonists |
| JP5724851B2 (ja) * | 2011-11-30 | 2015-05-27 | 東レ株式会社 | Ｎ−（ヨードフェニル）ピリミジニルアミン誘導体の製造方法 |
| HK1207403A1 (en) | 2012-04-19 | 2016-01-29 | Acetylon Pharmaceuticals, Inc. | Biomarkers to identify patients that will respond to treatment and treating such patients |
| WO2014059306A1 (en) | 2012-10-12 | 2014-04-17 | The Trustees Of The University Of Pennsylvania | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof |
| US9145412B2 (en) | 2012-11-02 | 2015-09-29 | Acetylon Pharmaceuticals, Inc. | Selective HDAC1 and HDAC2 inhibitors |
| US9139583B2 (en) | 2013-02-01 | 2015-09-22 | Acetylon Pharmaceuticals, Inc. | Selective HDAC3 inhibitors |
| JP2016511237A (ja) | 2013-02-01 | 2016-04-14 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 選択的ｈｄａｃ３阻害剤 |
| US20140357512A1 (en) | 2013-06-03 | 2014-12-04 | Acetylon Pharmaceuticals, Inc. | Histone deacetylase (hdac) biomarkers in multiple myeloma |
| JP2016531163A (ja) | 2013-09-20 | 2016-10-06 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | Ｈｄａｃ６阻害物質を用いた、異常なリンパ球の機能に起因する疾患の治療 |
| WO2015054099A1 (en) * | 2013-10-08 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase inhibitors and either her2 inhibitors or pi3k inhibitors |
| ES2818933T3 (es) | 2013-10-10 | 2021-04-14 | Acetylon Pharmaceuticals Inc | Inhibidores de la HDAC en combinación con los inhibidores de la pi3k, para el tratamiento del linfoma no Hodgkin |
| EP3055299B1 (en) | 2013-10-10 | 2021-01-06 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors |
| WO2015054197A1 (en) | 2013-10-10 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma |
| PE20161342A1 (es) | 2013-10-11 | 2016-12-31 | Acetylon Pharmaceuticals Inc | Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores |
| EP3060217B1 (en) | 2013-10-24 | 2022-06-08 | Mayo Foundation for Medical Education and Research | Treatment of polycystic diseases with an hdac6 inhibitor |
| EP3076973B1 (en) | 2013-12-03 | 2020-04-29 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase inhibitors and immunomodulatory drugs |
| US20150176076A1 (en) | 2013-12-20 | 2015-06-25 | Acetylon Pharmaceuticals, Inc. | Histone deacetylase 6 (hdac6) biomarkers in multiple myeloma |
| US9464073B2 (en) | 2014-02-26 | 2016-10-11 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors |
| US20150359794A1 (en) | 2014-06-13 | 2015-12-17 | Buck Institute For Research On Aging | Impairment of the large ribosomal subunit protein rpl24 by depletion or acetylation |
| CN107205988A (zh) | 2014-07-07 | 2017-09-26 | 埃斯泰隆制药公司 | 利用组蛋白脱乙酰酶抑制剂治疗白血病 |
| US20160137630A1 (en) | 2014-10-08 | 2016-05-19 | Acetylon Pharmaceuticals, Inc. | Induction of gata2 by hdac1 and hdac2 inhibitors |
| US20160158231A1 (en) | 2014-12-05 | 2016-06-09 | Vib Vzw | Pyrimidine hydroxy amide compounds for treating peripheral neuropathy |
| CN107438436A (zh) | 2014-12-05 | 2017-12-05 | 摩德纳和雷焦艾米利亚大学 | 用于治疗淋巴瘤的组蛋白脱乙酰酶抑制剂和苯达莫司汀的组合 |
| CA2970500C (en) | 2014-12-12 | 2023-08-29 | Acetylon Pharmaceuticals, Inc. | Piperidine derivatives as hdac1/2 inhibitors |
| WO2016168647A1 (en) | 2015-04-17 | 2016-10-20 | Acetylon Pharmaceuticals Inc. | Treatment of neuroblastoma with histone deacetylase inhibotrs |
| US10272084B2 (en) | 2015-06-01 | 2019-04-30 | Regenacy Pharmaceuticals, Llc | Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy |
| AR104935A1 (es) | 2015-06-08 | 2017-08-23 | Acetylon Pharmaceuticals Inc | Formas cristalinas de un inhibidor de histona deacetilasa |
| TWI706937B (zh) | 2015-06-08 | 2020-10-11 | 美商艾斯特隆製藥公司 | 製備蛋白質去乙醯酶抑制劑之方法 |
| JP7100018B2 (ja) | 2016-08-08 | 2022-07-12 | アセチロン ファーマシューティカルズ インコーポレイテッド | ヒストンデアセチラーゼ６阻害剤及びｃｄ２０阻害抗体の薬学的組み合わせならびにその使用 |
-
2016
- 2016-06-08 TW TW105118213A patent/TWI706937B/zh not_active IP Right Cessation
- 2016-06-08 ES ES16732810T patent/ES2769255T3/es active Active
- 2016-06-08 JP JP2017563541A patent/JP6873053B2/ja active Active
- 2016-06-08 CA CA2988594A patent/CA2988594C/en active Active
- 2016-06-08 MX MX2017015900A patent/MX369349B/es active IP Right Grant
- 2016-06-08 US US15/176,826 patent/US10144714B2/en active Active
- 2016-06-08 EP EP16732810.3A patent/EP3303304B1/en active Active
- 2016-06-08 AR ARP160101701A patent/AR105812A1/es unknown
- 2016-06-08 AU AU2016276573A patent/AU2016276573A1/en not_active Abandoned
- 2016-06-08 CN CN201680046553.8A patent/CN107922352B/zh not_active Expired - Fee Related
- 2016-06-08 WO PCT/US2016/036434 patent/WO2016200930A1/en not_active Ceased
-
2020
- 2020-11-13 AU AU2020267299A patent/AU2020267299B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX369349B (es) | 2019-11-06 |
| TW201718517A (zh) | 2017-06-01 |
| AU2020267299A1 (en) | 2020-12-10 |
| CA2988594A1 (en) | 2016-12-15 |
| CA2988594C (en) | 2023-08-15 |
| CN107922352A (zh) | 2018-04-17 |
| JP2018518486A (ja) | 2018-07-12 |
| EP3303304A1 (en) | 2018-04-11 |
| US20160355486A1 (en) | 2016-12-08 |
| EP3303304B1 (en) | 2019-11-20 |
| CN107922352B (zh) | 2021-08-06 |
| WO2016200930A1 (en) | 2016-12-15 |
| AU2016276573A1 (en) | 2018-01-04 |
| TWI706937B (zh) | 2020-10-11 |
| JP6873053B2 (ja) | 2021-05-19 |
| AU2020267299B2 (en) | 2022-07-07 |
| AR105812A1 (es) | 2017-11-15 |
| MX2017015900A (es) | 2018-11-09 |
| WO2016200930A9 (en) | 2017-02-23 |
| US10144714B2 (en) | 2018-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11001582B2 (en) | Solid state forms of Venetoclax and processes for preparation of Venetoclax | |
| AU2020267299B2 (en) | Methods of making protein deacetylase inhibitors | |
| US20220127259A1 (en) | Solid state forms of valbenazine | |
| US10710998B2 (en) | Compound and process | |
| TWI450896B (zh) | 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸 | |
| CN110381940B (zh) | Ag-10的制备方法、其中间体及其盐 | |
| KR102266680B1 (ko) | 벨리노스테트의 다형태 및 이의 제조 방법 | |
| CN107810189B (zh) | 用于制备氮芥衍生物的方法 | |
| AU2021374232A1 (en) | Process for preparing heterocyclic methanone compounds and aza-bicyclo intermediates thereof | |
| WO2020053795A2 (en) | Process for the preparation of acalabrutinib and its intermediates | |
| WO2026092417A1 (zh) | Jak抑制剂的中间体、晶型及制备方法 | |
| HK1250732B (en) | Process for preparation of nitrogen mustard derivatives | |
| NZ736564B2 (en) | Process for preparation of nitrogen mustard derivatives |